Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571704 | 0.85 | PPARG (0.52) | PPARGPPARACYP1A2 | |
| SCHEMBL9564637 | 0.79 | LMNA (0.68) | LMNAMTNR1AMTNR1BADRB1ADRB3 | |
| SCHEMBL5421055 | 0.76 | LMNA (0.59) | LMNAPPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL2731803 | 0.76 | LMNA (0.59) | LMNAPPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL8468149 | 0.76 | LMNA (0.59) | LMNAPPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL9283760 | 0.76 | LMNA (0.59) | LMNAPPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL5512521 | 0.75 | LMNA (0.57) | LMNAPPARGPPARAMTNR1AMTNR1B | |
| Biphenyl SCHEMBL6026340 | 0.74 | KMT2A (0.40) | PPARGPPARACYP1A2 | |
| SCHEMBL8651047 | 0.74 | LMNA (0.52) | LMNAMTNR1AMTNR1BALOX15ADRB1 | |
| SCHEMBL8934296 | 0.72 | LMNA (0.50) | LMNAMTNR1AMTNR1BALOX15ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019029-B2 | Skin whiteners containing hydroxytetronic acid derivatives | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2006-03-28 | — | — | US | disclosed |
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | THE NORTHWESTERN MUTUAL LIFE INSURANCE COMPANY, AS ADMINISTRATIVE AGENT | 2002-10-03 | — | — | US | disclosed |
| EP-0746551-B1 | OPTICALLY PURE 4-ARYL-2-HYDROXYTETRONIC ACIDS | UNIV OHIO STATE RES FOUND (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0804430-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5656662-A | TREATING OR PREVENTING ATHEROSCLEROTIC DISORDERS, INHIBITING INFLAMMATORY CYTOKINES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5504107-A | ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| US-5504108-A | ANTIAGGLOMERANTS, ANTIARTHRITIC AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| WO-1995032194-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995023139-A1 | OPTICALLY PURE 4-ARYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-08-31 | — | — | WO | disclosed |
| US-5399721-A | Anticoagulant; prepared from aldehyde | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141956-A1 | Skin whiteners containing hydroxytetronic acid derivatives | TYR, PPP6C, CYP26A1 | LMNA 3638/4885PPARG 274/4885PPARA 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.